Inhibition Of IGF1R by IGF-1R/IR Inhibitor OSI906 as a Targeted Therapy for Glioblastoma: In Vitro & in Vivo Studies

被引：0
|
作者：
Fernandez, M. C. [1 ]
Martin, A. [1 ]
Clement, F. [1 ]
Venara, M. C. [1 ]
Garcia Lombardi, M. [2 ]
Bergada, I [1 ]
Gutierrez, M. [1 ]
Pennisi, P. A. [1 ]
机构：
[1] Hosp Ninos Dr R Gutierrez, CONICET, Ctr Invest Endocrinol Dr Cesar Bergada, CEDIE,FEI,Div Endocrinol, Buenos Aires, DF, Argentina
[2] Hosp Ninos Dr R Gutierrez, Serv Oncol, Buenos Aires, DF, Argentina
来源：
HORMONE RESEARCH IN PAEDIATRICS | 2019年 / 92卷
关键词：
IGF1R; Pediatric glioma; OSI906;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP5
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [21] IGF1R targeted therapy in human osteosarcoma cell lines
    Yang, Jia-Lin
    Kuang, Jonanthan
    Crowe, Philip J.
    BONE, 2008, 43 : S111 - S111
  • [22] Combination strategies for OSI-906, a small molecule inhibitor of the insulin-like growth factor receptor, IGF-1R
    Buck, E.
    Eyzaguirre, A.
    Rosenfeld-Franklin, M.
    Ji, Q.
    Mulvihill, M.
    Wild, R.
    Epstein, D.
    Iwata, K.
    Haley, J.
    Pachter, J.
    Miglarese, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 43 - 43
  • [23] IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer
    Neuzillet, Yann
    Chapeaublanc, Elodie
    Krucker, Clementine
    De Koning, Leanne
    Lebret, Thierry
    Radvanyi, Francois
    Bernard-Pierrot, Isabelle
    BMC CANCER, 2017, 17
  • [24] IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer
    Yann Neuzillet
    Elodie Chapeaublanc
    Clémentine Krucker
    Leanne De Koning
    Thierry Lebret
    François Radvanyi
    Isabelle Bernard-Pierrot
    BMC Cancer, 17
  • [25] Combination treatment strategy of an IGF-1R kinase inhibitor, OSI-906 in models of progressive disease following initial respose to EGFR tyrosine kinase inhibition therapy
    Brown, Eric
    Silva, Stacia
    Pirritt, Caroline
    Wolf, Julie
    Epstein, David
    Wild, Robert
    Rosenfeld-Franklin, Maryland
    CANCER RESEARCH, 2009, 69
  • [26] Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma
    Abraham, Jinu
    Prajapati, Suresh I.
    Nishijo, Koichi
    Schaffer, Beverly S.
    Taniguchi, Eri
    Kilcoyne, Aoife
    McCleish, Amanda T.
    Nelon, Laura D.
    Giles, Francis G.
    Efstratiadis, Argiris
    LeGallo, Robin D.
    Nowak, Brent M.
    Rubin, Brian P.
    Malempati, Suman
    Keller, Charles
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (04) : 697 - 707
  • [27] 18FDG-PET Predicts Pharmacodynamic Response to OSI-906, a Dual IGF-1R/IR Inhibitor, in Preclinical Mouse Models of Lung Cancer
    McKinley, Eliot T.
    Bugaj, Joseph E.
    Zhao, Ping
    Guleryuz, Saffet
    Mantis, Christine
    Gokhale, Prafulla C.
    Wild, Robert
    Manning, H. Charles
    CLINICAL CANCER RESEARCH, 2011, 17 (10) : 3332 - 3340
  • [28] REDUNDANT INSULIN RECEPTOR AND IGF-1R SIGNALING IN GLIOBLASTOMA
    Gong, Yuanying
    Ma, Yufang
    Cheng, Zhixiang
    Thompson, Reid
    Wang, Jialiang
    NEURO-ONCOLOGY, 2013, 15 : 30 - 30
  • [29] Effects of IGF-1R Nuclear Localization in Glioblastoma Cells
    Martin, Ayelen
    Clement, Florencia
    Venara, Marcela
    Bergada, Ignacio
    Gutierrez, Mariana
    Pennisi, Patricia
    HORMONE RESEARCH IN PAEDIATRICS, 2018, 90 : 37 - 37
  • [30] Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer
    Buck, Elizabeth
    Gokhale, Prafulla C.
    Koujak, Susan
    Brown, Eric
    Eyzaguirre, Alexandra
    Tao, Nianjun
    Rosenfeld-Franklin, Maryland
    Lerner, Lorena
    Chiu, M. Isabel
    Wild, Robert
    Epstein, David
    Pachter, Jonathan A.
    Miglarese, Mark R.
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (10) : 2652 - 2664
12345